FDA — authorised 23 August 2024
- Application: BLA761298
- Marketing authorisation holder: AMGEN INC
- Local brand name: PAVBLU
- Indication: INJECTABLE — INJECTION
- Status: approved
🇺🇸 ABP 938 in United States
FDA authorised ABP 938 on 23 August 2024
Marketing authorisation
ABP 938 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Bone metabolism / Osteoporosis approved in United States
Frequently asked questions
Is ABP 938 approved in United States?
Yes. FDA authorised it on 23 August 2024.
Who is the marketing authorisation holder for ABP 938 in United States?
AMGEN INC holds the US marketing authorisation.